Janssen inks nference AI research pact

Flash-to-flash-to-cloud approach brings business value to enterprise data
This builds on recent artificial intelligence deals Janssen has penned with Iktos and BenevolentAI. (iStockPhoto/D3Damon)

Looking to broaden its use of artificial intelligence to help lock down its R&D work, Johnson & Johnson’s biotech unit Janssen has penned a new deal with AI specialist nference.

The multiyear deal, financial details of which were not disclosed, will see the Big Pharma “leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.”

In practical terms, this will see nference uncovering and prioritizing new targets and disease subsets as well as boosting effectiveness by matching the right patients to the right drugs. Further, nference will encourage efficiencies by identifying the optimal sites and investigators for pushing on with clinical trials across hospitals.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

To do this, nference said it has developed a “holistic data science kernel” that will synthesize some of the Janssen R&D databases with “real-time insights gleaned by the core nference AI platform from the world’s public biomedical knowledge bases.”

It added: “This will include synthesis of unstructured, semi-structured and structured data sets that evolves and learns continuously as expert- and machine-curated insights are fed into the platform by nference and Janssen R&D scientists.”

RELATED: Mayo Clinic startup raises series A round for AI-driven R&D

This comes a month after Janssen tied up with French AI firm Iktos—which describes its work as being borne of “deep generative models”—to work on new tech for in silico drug design that aims to boost drug discovery based on “its unique capacity to explore chemical space with speed and efficiency, thus enabling identification of molecules that meet the desired criteria in a given research project.” This deal also builds on the 2016 drug discovery collaboration with BenevolentAI.

RELATED: BenevolentAI looks to artificial intelligence for speedy development of in-licensed drugs

“We are thrilled to be advancing this strategic alliance with Janssen R&D for connecting biological information to disease condition and therapeutic mechanisms,” said Venky Soundararajan, Ph.D., founder and chief scientific officer of nference.

“By pairing the unique data science technologies enabled by the nference platform with the renowned institutional expertise of Janssen R&D, we seek to unearth answers to complex research questions and solve urgent business needs. This is enabled via an agile data science-enabled business platform and a living software kernel that continually synthesize public as well as proprietary knowledge across therapeutic areas and global support functions.”

On top of this, life science veteran, genome sequencing father and MIT professor George Church, Ph.D., has become the new chair of nference’s scientific board.

He adds: “This alliance heralds the coming together of breakthrough machine intelligence, profound biomedical insights and iterative software application development to power drug discovery, disease stratification and clinical development for one of the largest pharmaceutical companies.”

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.